Introducing the Pharma 2020 Series

These reports look into the future of the Pharmaceuticals and Life Sciences’ value chain. And they include an analysis of the strategies available to companies.
Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike.

This report, published in June 2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and providers, can address the changing needs of society more effectively.

Published in February 2009, this paper discusses the key forces reshaping the pharmaceutical marketplace, including the growing power of healthcare payers, providers and patients, and the changes required to create a marketing and sales model that is fit for the 21st century. These changes will enable the industry to market and sell its products more cost-effectively, to create new opportunities and to generate greater customer loyalty across the healthcare spectrum.

Fourth in the Pharma 2020 series and published in April 2009, this report highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry.

In our sixth release of the series, published in February 2011, PwC discusses how pharma companies must develop different supply chain models, learn to use supply chains as a market differentiator and revenue generator, and recognise how information will drive the downstream flow of products and services.

All these publications are available to download at: www.pwc.com/pharma2020
The global market for medicines is growing but the industry must transform to capitalise opportunities

Pharma’s strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters worked well for many years, but its R&D productivity has now plummeted and the environment’s changing. PwC\(^1\) believes that seven major trends are reshaping the marketplace:

- the burden of chronic disease is soaring – placing even greater pressure on already stretched healthcare budgets
- healthcare policy-makers and payers are increasingly mandating what doctors can prescribe
- a growing number of healthcare payers are measuring the pharmacoeconomic performance of different medicines. A widespread use of electronic medical records will give them the data they need to insist on outcomes-based pricing
- the boundaries between different forms of healthcare are blurring, as clinical advances render previously fatal diseases chronic and the self-medication sector expands
- demand for medicines is growing more rapidly in the emerging economies than the industrialised economies
- governments everywhere are beginning to focus on prevention rather than treatment, although they have not yet invested very much in pre-emptive measures; and
- the regulators are becoming more cautious about approving truly innovative medicines.

These trends will compound the challenges Pharma already faces, but they’ll also provide some major opportunities. So what must the industry do to capitalise on them? We think that it’ll have to improve its understanding of disease, reduce its R&D costs significantly and spread its bets to improve its productivity. It’ll also have to tap the potential of the emerging economies and switch from selling medicines to managing outcomes. However, few, if any, companies will be able to perform these activities alone.

\(^1\) “PwC” refers to the network of member firms of PricewaterhouseCoopers International Limited (PwCIL), or, as the context requires, individual member firms of the PwC network.
Taking R&D to the virtual level

Let’s begin with R&D. If Pharma’s to develop safe, efficacious new medicines more economically, it’ll have to learn much more about how the human body functions at the molecular level and the pathophysiological changes disease causes. Only then will it be able to develop a better understanding of how to modify or reverse these changes. This is a huge task – but one that several emerging technologies can help to facilitate.

Semantic technologies will, for example, make it much easier to identify the links between a particular disease and the biological pathways it affects, or the links between a particular molecule and its impact on the human body. Similarly, computer-aided molecule design will give researchers a much better starting point in the search for potent molecules.

Various academic institutes and bioinformatics firms are also building computer models of different organs and cells, with the ultimate aim of creating a “virtual man”. Developing such a model will require a massive collaborative effort far exceeding that needed to complete the Human Genome Project. Nevertheless, predictive biosimulation’s already playing a growing role in the R&D process and we anticipate that, by 2020, virtual cells, organs and animals will be widely employed in pharmaceutical research (see Figure 1).

Of course, even the most robustly modelled molecules will still have to be tested in real human beings. But here too, we expect some dramatic changes. When biomarkers for diagnosing and treating patients more accurately are more widely available, for example, the industry will be able to stratify patients with different but related conditions and test new medicines only in patients who suffer from a specific disease subtype. That will allow the industry to reduce the number and size of the clinical studies required to prove efficacy. Semantic technologies will also play a major role in improving the development process, while pervasive monitoring will help Pharma track patients on a real-time basis wherever they are.
Companies will use virtual R&D to increase innovation and reduce commercial deficit

We think that these scientific and technological advances will ultimately render the current model of development, with its four distinct phases of clinical testing, defunct. A company will start by administering a treatment to a single patient who has been screened to ensure that he or she has the right medical profile. Once there’s evidence that the treatment doesn’t cause any immediate adverse events, it’ll be sequentially administered to other patients – from as few as 20 to as many as 100. The data they generate will be compared to data from the modelling that preceded the study and subjected to techniques like Bayesian analysis to adapt the course of the study, but the study itself will be conducted in a single, continuous phase (see Figure 2).

The development process will also become much more iterative, with data on a molecule for one disease subtype getting fed back into the development of new molecules for other disease subtypes in the same cluster of related diseases. And the current system of conducting trials at multiple sites will be replaced with a system based on independently managed clinical supercentres.

The regulatory process will change equally substantially over the next decade. First, there’ll be a common regulatory regime for all healthcare products and services, rather than separate regimes for pharmaceuticals, medical devices, diagnostics and the like. Indeed, there may even be a single global system, administered by national or federal agencies responsible for ensuring that new treatments meet the needs of patients within their respective domains, although we think the latter is less likely.

Second, the current ‘all-or-nothing’ approach to the approval of new medicines will be replaced by a cumulative process, based on the gradual accretion of data. In other words, all newly approved therapies will receive “live licences” conditional on further in-life testing to substantiate their safety and efficacy in larger populations, different populations or the treatment of other conditions.

But, if they are to capitalise on the new technologies now emerging and the creation of a nimble, more collaborative regulatory regime, many companies will have to make significant organisational and behavioural changes. They’ll, for example, have to decide whether they want to focus on mass-market medicines or speciality therapies, and whether they want to outsource most of their research or keep it in-house. Those that regard R&D as an integral part of their activities may also need to review the way they manage their R&D and remunerate their scientific staff.

Figure 2: What the development process might look like in 2020
Getting the medicines to the marketplace

We’ve noted that the pharmaceutical industry is experiencing major upheavals associated with the need to move to more efficient models for discovery, development and selling of the medicines to which many companies have responded in different ways. However, they’ve invested relatively little effort in reconfiguring their manufacturing and distribution operations to date. Yet a significant amount of the cost base of most bio-pharmaceutical companies comes from the supply chain. It’s the link between the laboratory and the marketplace and includes everything from sourcing raw materials to manufacturing and packaging to inventory warehousing, transportation and distribution.

As demand grows for more customised products and services – and as the nature of those products and services becomes more complex – the next generation of supply chains will become an increasingly important source of differentiation for makers of medicines. It’ll also play a more prominent part in the strategic thinking of industry leaders.

We believe there are numerous trends that are reshaping the environment in which the industry operates and which are dictating the need for a different way for the pharmaceutical companies to make and distribute their products.

By 2020, the more diverse product types and therapies with shorter product lifecycles; new ways for assessing, approving and monitoring medicines; increasing emphasis on outcomes; new modes of delivering healthcare where the care is pushed into the community and where access to information on patients will become as important as the products themselves; the growing importance of emerging markets; a greater public scrutiny impacting the ability to manage risk and compliance; and, tougher environmental controls and regulations will oblige companies to strategically reassess their supply chain approach. (see Figure 3)

---

**Figure 3: Numerous forces are dictating the need for a different sort of supply chain**

<table>
<thead>
<tr>
<th></th>
<th>New product types</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>More complex manufacturing and distribution processes</td>
</tr>
<tr>
<td></td>
<td>Different supply chains for different product types</td>
</tr>
<tr>
<td></td>
<td>Shorter product lifecycles</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Live licensing</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Incremental launch of new medicines</td>
</tr>
<tr>
<td></td>
<td>Ability to scale up and down very rapidly</td>
</tr>
<tr>
<td></td>
<td>Step changes in the revenue curve</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Increasing emphasis on outsources</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Expansion into health management services</td>
</tr>
<tr>
<td></td>
<td>Leaner and more adaptable cost structure that preserves gross margins at every stage of the product lifecycle</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>New modes of healthcare delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Blurring of the boundaries between primary and acute care</td>
</tr>
<tr>
<td></td>
<td>Much wider distribution network</td>
</tr>
<tr>
<td></td>
<td>Demand-driven manufacturing and distribution processes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Growing importance of emerging markets</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Offerings designed for patients in emerging markets</td>
</tr>
<tr>
<td></td>
<td>More widely dispersed and more robust supply chain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Greater public scrutiny</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Heavier regulation</td>
</tr>
<tr>
<td></td>
<td>Robust risk assessment and risk-management capabilities across the extended supply chain</td>
</tr>
</tbody>
</table>

Source: PwC
We believe that timely access to various emerging technologies will help to increase the efficiency of the manufacturing and distribution functions. It will also redefine the interface with the patient bringing pharma companies even closer to patients. Additionally, more collaboration between the parties involved in healthcare provision will contribute to make the industry more efficient. The supply chains for designing, manufacturing and distributing pharmaceuticals and medical devices plus those providing healthcare services will integrate. The aim is that all partners can see the full picture and can plan ahead more accurately and cost-effectively.

The successful pharmaceutical companies of the future will be those that integrate all these opportunities and build supply chains with new manufacturing, distribution and service-management techniques. We outline four potential scenarios. Depending on their product and channel portfolio, most companies will have to manage more than one scenario simultaneously.

Companies that concentrate on specialist therapies might exit from manufacturing altogether and, instead, become a virtual manufacturer. They’ll outsource the entire supply from production of the earliest clinical batches to full-scale manufacturing, packaging and distribution through a network of integrated supply partners (see Figure 6).

Alternatively, they might position themselves as service innovators, building supply chains that are capable of manufacturing and distributing complex treatments as well as managing multiple suppliers of integrated, valued-added health management services.

Mass-market manufacturers, such as the makers of generics, might position themselves as high-volume, low-cost providers, borrowing lessons in lean manufacturing, strategic pricing and inventory management from the consumer products industry. Another option for mass market manufacturers is to turn their supply chains into profit centres that combine economic manufacturing and distribution of satellite services, such as direct-to-patient delivery, secondary packaging or distribution to hospitals and pharmacies. They’ll then franchise those profit centres as a stand-alone offering for both internal and external customers.

By 2020, the most successful companies will be those that seize the initiative and start building agile, efficient supply chains which bring them closer to the patient.
Figure 4: Four options exist for restructuring the pharmaceutical supply chain

<table>
<thead>
<tr>
<th>Operations strategy</th>
<th>Specialist Therapies</th>
<th>Mass-market medicines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virtual manufacturer</td>
<td>Create a virtual network of integrated supply partners</td>
<td>Build a service-oriented supply chain to enhance brands and differentiate company from its competitors</td>
</tr>
<tr>
<td>Service innovator</td>
<td>Build a service-oriented supply chain to enhance brands and differentiate company from its competitors</td>
<td>Build a reliable, ‘no-frills’ supply chain to deliver products as economically as possible</td>
</tr>
<tr>
<td>Low-cost provider</td>
<td>Combine agile, economic manufacturing and distribution with the provision of satellite service to generate profits</td>
<td></td>
</tr>
</tbody>
</table>

Source: PwC

In all four cases, the supply chain of the future will need to be much more patient-focused. In a world where outcomes count for everything, it’s not molecules that create value but, rather, the ability to integrate data, products and services in a coherent care package. Understanding this shift of emphasis from products to patient outcomes is key. Those organisations that recognise the shift will be able to deliver significant benefits to every stakeholder in the healthcare value chain: payers, providers, patients and shareholders.
A new approach to marketing and sales

The industry’s marketing and sales model will likewise have to undergo major alterations, as pay-for-performance becomes the norm in many countries and the opportunities for generating value from pure product offerings diminish. Many companies will have to analyse their own value chains to identify opportunities for working more closely with healthcare payers and providers. They will, for instance, have to consult payers, providers and patients when deciding which compounds to progress through their pipelines. Some companies now look at whether the products they’re developing are more effective than other existing therapies. Very few focus on understanding the payer’s perspective. We believe that all companies should extend the concept of “de-risking” from the clinical to the commercial sphere to ensure that they’re making medicines the market really wants to buy (see Figure 5).

Similarly, many companies will have to supplement the therapies they develop with a wide range of health management services. Most treatments perform much better in clinical trials than they do in everyday life, partly because the level of compliance is much higher. Any pharmaceutical company that wants to command premium prices for its therapies will have to provide a range of products and services from which patients can choose all but the core prescription. They will need to help patients manage their health.

This route has several significant advantages. It’ll enable companies to generate new sources of revenue, differentiate their offerings more effectively and protect the value of the medicines they make. But it’ll also entail the formation of numerous alliances with local service providers and even rival manufacturers; the development of a secure, interoperable technological infrastructure; the management of new intellectual rights issues; the creation of much stronger brands; and the redefinition of the industry’s role. Instead of trying to stimulate prescription sales, its task will be to help patients manage the disease lifecycle.

The shift to performance-based pricing will dictate other changes, too,

Smaller, refocused sales forces will enable pharma companies to create greater value for patients

<table>
<thead>
<tr>
<th>Phase</th>
<th>Percentage of Spending</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preclinical</td>
<td>25.7</td>
</tr>
<tr>
<td>Phase I</td>
<td>5.8</td>
</tr>
<tr>
<td>Phase II</td>
<td>11.7</td>
</tr>
<tr>
<td>Phase III</td>
<td>25.5</td>
</tr>
<tr>
<td>Regulatory</td>
<td>6.9</td>
</tr>
<tr>
<td>Phase IV</td>
<td>13.3</td>
</tr>
</tbody>
</table>

Figure 5: Pharma needs to use a price de-risking strategy in early development

Source: PwC
including the need for a more flexible approach to pricing. The introduction of live licences and increasing importance of the emerging markets will reinforce this trend. Any company that launches a new healthcare package will have to negotiate price rises in line with the extension of the terms on which that package can be marketed. And if it wants to establish a stronger footing in the emerging world, it’ll have to use differential pricing – both within and between countries.

Increasing payer pressure on pricing and outcomes is forcing companies to increase its efforts to improve patient compliance. Improved patient compliance provides numerous benefits, not least, individual health outcomes, but it also helps to drive healthcare cost and improved revenues for companies. With performance based pricing becoming more common, a focus on patient compliance through education and technology will be a necessity.

Lastly, the industry leaders will have to develop comprehensive strategies for marketing and selling specialist healthcare packages, a process that will require the development of new skills and routes to market; and they’ll have to revolutionise their marketing and sales functions. By 2020, the role of the traditional sales representative will be largely obsolete. Conversely, the industry will have a much greater need of people with the expertise to build brands; manage a network of external alliances; negotiate with governments and health insurers; liaise with secondary-care specialists; and communicate with patients.

The need for new business models

The changes we’ve outlined above will all necessitate the development of multinational, multi-disciplinary networks drawing on a much wider range of skills than Pharma alone can provide. Most companies will therefore need to adopt new business models.

We believe that two principal models – federated and fully diversified – will emerge. The federated model comprises a network of separate organisations linked by a shared purpose and infrastructure. The fully diversified model comprises a network of entities owned by a single parent company. We’ve also identified two variants of the federated model. In the virtual version, a company outsources most or all of its activities; in the venture version, it manages a portfolio of investments (see Figure 6).

These models are not mutually exclusive. A fully diversified company might choose to use a federated model for certain aspects of its business, and vice versa. But we think that the federated model will ultimately dominate, primarily because it’s quicker and more economic to implement.

The transition will not be easy, because collaborative business models are far more complex than the integrated model that’s previously prevailed.
Disrupting the existing order can also have a major impact on a company’s short-term performance. We anticipate that many companies which choose the federated model will adopt a progressive approach. They’ll start with opportunistic alliances; use the most successful alliances as building blocks to create more strategic, longer-lasting coalitions; and, finally, use the most successful coalitions to create a fully federated network of long-term partners.

The prospects for any pharmaceutical company that can make the switch are very promising. To date, Pharma has focused on the profits it can earn from the estimated 10-15% of the health budget that goes on medicines. Yet there are many opportunities to generate revenues by improving the way in which the remaining 85-90% is spent. It’s these opportunities the industry will need to address in the brave new world of 2020.

Figure 6: The different business models

<table>
<thead>
<tr>
<th>Collaborative: Federated model</th>
<th>Owned: Fully Diversified model</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Network of separate entities</td>
<td>• Network of entities owned by one parent company</td>
</tr>
<tr>
<td>• Based on shared goals and infrastructure</td>
<td>• Based on provision of internally integrated product-service mix</td>
</tr>
<tr>
<td>• Draws on in-house and/or external assets</td>
<td>• Spreads risk across business units</td>
</tr>
<tr>
<td>• Combines size with flexibility</td>
<td></td>
</tr>
</tbody>
</table>

Virtual variant
- Network of contractors
- Activities coordinated by one company acting as hub
- Operates on project-by-project basis
- Fee-for-service financial structure

Venture variant
- Portfolio of investments
- Based on sharing of intellectual property/capital growth
- Stimulates entrepreneurialism and innovation
- Spreads risk across portfolio

Source: PwC
A heavier tax burden

The collaborative business models will enable Pharma to deliver healthcare packages that comprise medicines and supporting services supplied locally (such as drug administration training, home delivery, physiotherapy, health screening and exercise facilities). This new way of doing business, combined with the political and economic trends already shaping the general commercial environment, will have major tax repercussions. We anticipate that the industry’s corporate tax burden will rise significantly over the next 10 years — unless it undertakes various strategies to mitigate the impact.

Governments of the industrialised world will struggle to repair public finances damaged by debts accrued in managing the global recession. They’ll decrease the opportunities that have allowed the industry to reduce corporate taxes by moving profits from higher-tax to lower-tax territories. Along with imposing more stringent tax regulations, the major powers could place trading restrictions on traditional tax havens that refuse to cooperate. The tax authorities in most countries will work more closely with their counterparties in other territories to control multinationals’ tax-reducing practices.

As Big Pharma moves toward the provision of integrated healthcare packages, the proportion of income generated in the industry’s end markets will increase. Demand for such services initially is likely to be greatest in the industrialised world, where corporate income tax rates are often higher. That will make it more difficult for companies to assign profits legitimately from high- to low-tax jurisdictions.

Undertaking or managing more business activities in end markets will also make it harder to prove that a company has not created a permanent business establishment in countries where services are delivered. This may increase the risk of failing to obtain double tax relief, as allowed under international tax treaties, and of being taxed on the same earnings in the home country and the country where the services have been delivered.

The provision of direct-to-patient services will additionally make it even more difficult for the industry to negotiate its way through the maze of withholding tax regulations. Countries have traditionally adopted a more diverse approach to the application of withholding taxes to payments for services than they have for goods. These variations can produce more material for tax disputes.
The provision of services also may affect the way the income of controlled foreign corporations (CFCs) is taxed. In many developed countries, tax laws provide that CFC profits may be attributed to the holding company and taxed immediately, rather than being taxed only when (and if) they are repatriated. However, CFC legislation often distinguishes between ‘passive’ income (i.e., interest, dividends, annuities, rents and royalties), which is taxed, and ‘active’ income (i.e., income from commercial activities), which is not taxed. Some of the new healthcare services pharmaceutical multinationals will provide may fall into the taxable category.

Providing integrated packages also could increase compliance costs and risks associated with indirect taxes, such as value-added tax (VAT). Some VAT regimes may apply the appropriate rate of VAT to each component of a package, while others may treat the package as a composite and apply the rate of the principal element to the entire bundle.

The increasing importance of emerging markets, an evolving supply chain, and a shift to services could also have a major bearing on customs duties and other trade-related tariffs pharmaceutical companies incur. Some countries levy significant import duties on key active pharmaceutical ingredients and finished products, and the valuation of combined product-service offerings for customs purposes could prove complicated.

Finally, because of more complex supply chains, it may become more difficult to use transfer pricing — i.e., the allocation of income among related business entities via the pricing of intellectual property, tangible goods, services, and loans or other financial transactions — to avoid double taxation. Many tax authorities already are clamping down on abusive transfer pricing practices, such as shifting profits artificially from a high- to a low-tax jurisdiction, by maximising expenses in the former and income in the latter.

To deal with these multiple pressures, companies will need to rethink their tax strategies. The choice of legal entity and structure of commercial arrangements, for example, will have a significant impact on taxation. One solution for multinationals might be to locate more business activities, such as R&D, manufacturing, and marketing, in regional hubs in low-tax countries. Some might choose to move their entire operations to a low-tax location.

On the positive side, the competition to attract companies engaging in R&D will intensify. Some countries will offer generous tax incentives and credits — and several will be new competitors keen to build knowledge-based economies. Tax departments will need to keep abreast of these incentives so they can advise leadership on how to take advantage of tax-reduction opportunities.

Tax departments will also have to build much closer relationships with the operational parts of the business and acquire a much more detailed understanding of the complexities of supply chain arrangements. Those tax departments that combine a strong grasp of long-term strategy and effective lobbying with a detailed tactical understanding of the way in which products are distributed and value is created will be best placed to help pilot their companies along the path to future prosperity.

Tax strategy will be the crux, not an afterthought, of long-term business plans
# Territory contacts

<table>
<thead>
<tr>
<th>Country</th>
<th>Name</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>Diego Niebuhr</td>
<td>[54] 11 4850 4705</td>
</tr>
<tr>
<td>Australia</td>
<td>John Cannings</td>
<td>[61] 2 826 66410</td>
</tr>
<tr>
<td>Austria</td>
<td>Doris Bramo-Hackel</td>
<td>[43] 1 501 88 3232</td>
</tr>
<tr>
<td>Belgium</td>
<td>Thierry Vanwelkenhuyzen</td>
<td>[32] 2 710 7422</td>
</tr>
<tr>
<td>Bolivia</td>
<td>Cesar Lora</td>
<td>[591] 721 47235</td>
</tr>
<tr>
<td>Brazil</td>
<td>Eliane Kihara</td>
<td>[55] 11 3674 2455</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>Irina Tsvetkova</td>
<td>[359] 2 9355 126</td>
</tr>
<tr>
<td>Canada</td>
<td>Gord Jans</td>
<td>[1] 905 897 4527</td>
</tr>
<tr>
<td>China</td>
<td>Mark Gilbraith</td>
<td>[86] 21 2323 2898</td>
</tr>
<tr>
<td></td>
<td>Jia Xu</td>
<td>[86] 10 6533 7734</td>
</tr>
<tr>
<td>Colombia</td>
<td>María Helena Díaz</td>
<td>[57] 1 634 0320</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>Radmila Fortova</td>
<td>[420] 2 5115 2521</td>
</tr>
<tr>
<td>Denmark</td>
<td>Torben TOJ Jensen</td>
<td>[45] 3 945 92433</td>
</tr>
<tr>
<td></td>
<td>Erik Todbjerg</td>
<td>[45] 3 945 9433</td>
</tr>
<tr>
<td>Ecuador</td>
<td>Carlos Cruz</td>
<td>[593] 2 2562 288 130</td>
</tr>
<tr>
<td>Estonia</td>
<td>Peep Kalamäe</td>
<td>[372] 6141 976</td>
</tr>
<tr>
<td>Finland</td>
<td>Janne Rajalahti</td>
<td>[358] 3 3138 8016</td>
</tr>
<tr>
<td>France</td>
<td>Anne-Christine Marie</td>
<td>[33] 1 5657 1342</td>
</tr>
<tr>
<td>Germany</td>
<td>Georg Kämpfer</td>
<td>[49] 69 9585 1333</td>
</tr>
<tr>
<td>Greece</td>
<td>Nick Papadopoulos</td>
<td>[30] 210 687 4740</td>
</tr>
<tr>
<td>Hungary</td>
<td>Eva Barsi</td>
<td>[36] 1 461 9169</td>
</tr>
<tr>
<td>India</td>
<td>Sujay Shetty</td>
<td>[91] 22 6669 1305</td>
</tr>
<tr>
<td>Indonesia</td>
<td>Eddy Rintis</td>
<td>[62] 21 5212901</td>
</tr>
<tr>
<td>Ireland</td>
<td>John M Kelly</td>
<td>[353] 1 792 6307</td>
</tr>
<tr>
<td></td>
<td>Enda McDonagh</td>
<td>[353] 1 792 8728</td>
</tr>
<tr>
<td>Israel</td>
<td>Assaf Shemer</td>
<td>[972] 3 795 4681</td>
</tr>
<tr>
<td>Italy</td>
<td>Nicola Nicoletti</td>
<td>[39] 026 6720504</td>
</tr>
<tr>
<td>Japan</td>
<td>Kenichiro Abe</td>
<td>[81] 80 3158 5929</td>
</tr>
<tr>
<td></td>
<td>Eimei Shu</td>
<td>[81] 3 5293 1032</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>Richard Bregonje</td>
<td>[77] 27 298 448</td>
</tr>
<tr>
<td>Korea</td>
<td>Henry An</td>
<td>[82] 2 3781 2594</td>
</tr>
<tr>
<td>Latvia</td>
<td>Vita Sakne</td>
<td>[371] 67094425</td>
</tr>
<tr>
<td>Lithuania</td>
<td>Kristina Krisciunaitė</td>
<td>[370] 5 239 7365</td>
</tr>
</tbody>
</table>
Luxembourg
Laurent Probst
[352] 0 494 848 2522

Malta
Adrian Spiteri
[356] 2564 7038

Mexico
Jorge Luis Hernández Baptista
[52] 55 5263 6106

Netherlands
Arwin van der Linden
[31] 20 5684712

Norway
Fredrik Melle
[47] 95 26 00 13

Peru
Felix Horna
[511] 211 6500

Philippines
Che Javier
[63] 2 845 2728

Poland
Mariusz Ignatowicz
[48] 22 523 4795

Portugal
Ana Lopes
[351] 213 599 159

Romania
Mihaela Mitroi
[40] 21 225 3717

Russia
Alina Lavrentieva
[7] 495 967 6250

Singapore
Abhijit Ghosh
[65] 6236 3888

Slovakia
Rastislava Krajcovica
[421] 2 5935 06 16

South Africa
Denis von Hoesslin
[27] 117 974 285

Spain
Rafael Rodríguez Alonso
[34] 91 568 4287

Sweden
Mikael Scheja
[46] 8 555 33 038

Switzerland
Clive Bellingham
[41] 58 792 2822

Taiwan
Elliot Liao
[886] 3 5780205 26217

Thailand
Zoya Vassilieva
[66] 2 344 1115

Turkey
Zeki Gunduz
[90] 212 326 64 100

Ukraine
Ron Barden
[380] 44 490 6777

United Arab Emirates
Sally Jeffery
[971] 4 304 3154

United Kingdom
Andrew Packman
[44] 1895 522104

United States
Michael Swanick
[1] 267 330 6060

Uruguay
Richard Moreira
[598] 2916 0463

Venezuela
Luis Freites
[58] 212 700 6966
About Global Pharmaceuticals and Life Sciences Industry Group

PwC firms provide industry-focused assurance, tax and advisory services to enhance value for their clients. More than 161,000 people in 154 countries in firms across the PwC network share their thinking, experience and solutions to develop fresh perspectives and practical advice.

Our Global Pharmaceuticals and Life Sciences Industry Group has experience working with companies on industry-specific strategic, operational, and financial issues. As well as assurance, tax and advisory services, we also have specialised capabilities in regulatory compliance, risk management, performance improvement and transaction support.

Simon Friend  
Partner, Global Pharmaceuticals and Life Sciences Industry Leader  
simon.d.friend@uk.pwc.com  
[44] 20 7213 4875

Dr. Steve Arlington  
Partner, Global Pharmaceuticals and Life Sciences Advisory Services Leader  
steve.arlington@uk.pwc.com  
[44] 20 7804 3997

Michael Swanick  
Partner, Global Pharmaceuticals and Life Sciences Tax Leader PwC (US)  
michael.f.swanick@us.pwc.com  
[1] 267 330 6060

Attila Karacsony  
Director, US Pharmaceuticals and Life Sciences Marketing  
attila.karacsony@us.pwc.com  
[1] 973 236 5640

Marina Bello Valcarce  
Global Pharmaceuticals and Life Sciences Marketing and Knowledge Management  
marina.bello.valcarce@uk.pwc.com  
[44] 20 7212 8642

www.pwc.com/pharma

This publication has been prepared for general guidance on matters of interest only, and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, PricewaterhouseCoopers does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.

© 2011 PwC. All rights reserved. Not for further distribution without the permission of PwC. “PwC” refers to the network of member firms of PricewaterhouseCoopers International Limited (PwCIL), or, as the context requires, individual member firms of the PwC network. Each member firm is a separate legal entity and does not act as agent of PwCIL or any other member firm. PwCIL does not provide any services to clients. PwCIL is not responsible or liable for the acts or omissions of any of its member firms nor can it control the exercise of their professional judgment or bind them in any way. No member firm is responsible or liable for the acts or omissions of any other member firm nor can it control the exercise of another member firm's professional judgment or bind another member firm or PwCIL in any way.

HB8684